product safety
The safety of our products is paramount. To ensure that are products are free from pathogens, innovative technologies like the INTERCEPT™ Blood System for Plasma and nanofiltration are integrated into our manufacturing process.
pathogen reduction of human plasma
safety step 1: INTERCEPT™ Blood System for Plasma
Safety Step 1: The INTERCEPT Blood System for Plasma uses a process called pathogen inactivation. This technique employs the use of amotosalen, a photosensitive molecule, which, when exposed to ultraviolet (UV) light, forms covalent bonds with the nucleic acids of pathogens, effectively inactivating them. By preventing these pathogens from replicating, the risk of transfusion-transmitted infections is reduced. This process is especially effective against a wide range of viruses, bacteria, and parasites that might be present in the plasma.
nanofiltration
safety step 2: Nanofiltration
Safety Step 2: Nanofiltration is a physical process that involves passing our product through filters with pores in the 20 nanometer size range. For comparison, a hair is 50,000 to 100,000 nanometers in diameter! These ultra-small pores are specifically designed to trap and remove viruses based on their size, irrespective of their ability to replicate or their resistance to chemical inactivation. By doing so, nanofiltration provides an additional layer of safety by catching pathogens that might have escaped or are resistant to chemical treatments.
When combined, the INTERCEPT system and nanofiltration offer a comprehensive approach to blood safety. While the INTERCEPT system targets the nucleic acids of pathogens, ensuring they can’t replicate, nanofiltration acts as a secondary barrier, physically removing any potential residual contaminants based on size. The use of both these technologies in tandem can produce a near-sterile blood product, further ensuring the safety of recipients.
learn more about:
human plasma
our products
Our therapeutic formulation is suitable for a variety of products, including liquid eye drops, gels, ointments, contact lenses, contoured bandages, and wound dressings. We believe this formulation will promote healing of epithelial (surface cell) disorders, such as dry eye disease, ophthalmic burns, and chronic wounds.
our platform
Our platform leverages plasma from donated human blood and a proprietary antimicrobial molecule (form of chitosan). The tissue-repairing benefits of plasma-derived products, combined with the sustained action of chitosan, may provide relief and long-lasting therapeutic action.
INTERCEPT™ is a registered trademark of Cerus Corporation, Concord, CA